10-Q · May 20, 2026
Cosmos Health reported a substantial revenue increase of 30.7% year-over-year for Q1 2026, reaching $17,927,892, although they experienced a significant net loss of $2,805,423, indicating ongoing challenges in…
Earnings analysis · 10-Q
COSM earnings analysis
Filed August 18, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment data, or MD&A, so current-quarter revenue, margins, EPS, cash flow, and quantitative guidance cannot be…
Read full summary
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment data, or MD&A, so current-quarter revenue, margins, EPS, cash flow, and quantitative guidance cannot be assessed. The principal disclosed development is a high-risk control environment: management concluded disclosure controls were ineffective because of 2 material weaknesses. Remediation is underway with a third-party consultant, but its evaluation remained ongoing and the final report had not been received as of August 18, 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control Remediation Underway
Management states that a third-party consultant has been engaged to assist with control design, implementation, and gap evaluation; the consultant’s final report had not yet been received as of the filing date.
-
Independent Audit Committee
The Audit Committee consists of 3 independent directors: Anastasios Aslidis, John Hoidas, and Demetrios Demetriades.
-
Formal Audit Oversight
The Audit Committee is required to meet no less frequently than 4 times per year, with additional meetings as circumstances warrant.
What to watch
-
Ineffective Disclosure Controls
Management concluded that disclosure controls and procedures were ineffective as of the period end because of 2 identified weaknesses: inadequate supervision and segregation of duties, and ineffective IT general controls covering incompatible duties, program changes, and user access.
-
IT General Control Deficiencies
The IT control weakness includes 3 specific areas—segregation of incompatible duties, program change management, and user access controls—raising the risk of inaccurate or delayed financial reporting until remediation is validated.
-
Remediation Status Unresolved
Remediation is not complete: the consultant’s evaluation remained ongoing and no final report had been received as of the August 18, 2026 filing date. Management also states that successful remediation requires review and evidence of effectiveness before concluding that controls are effective.
Management's outlook
The supplied filing extract contains no MD&A, quantitative outlook, or explicit revenue/EPS guidance. Financial statement and guidance data were not available in the provided text.
Earlier filings 4
10-K · April 15, 2026
Cosmos Health describes a vertically integrated healthcare model combining generics, nutraceuticals, manufacturing, distribution, telehealth (ZipDoctor) and an AI drug‑repurposing platform (Cloudscreen). The filing…
10-Q · August 18, 2025
Cosmos Health reported Q2 revenue of $14,745,702 (up from $13,206,717 in Q2 2024) with gross profit of $1,163,814 and a quarterly net loss of $2,828,068 (basic/diluted loss per share $0.10). Gross margin improved to…
10-K · April 15, 2025
Cosmos Health presents a vertically integrated healthcare model spanning generics, nutraceuticals (≈165 SKUs), biocides, manufacturing/CMO services, telehealth (ZipDoctor) and an AI drug‑repurposing platform…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.